GLP-1 adherence tips: what TikTok gets right and wrong

What did @notdaniflores_ actually say?

The short version: she's been on tirzepatide for about eight months, takes breaks because the nausea gets bad, stopped three weeks ago, and now feels stuck. "I've been at the same number for like the past three four months," she says, and she's wondering whether starting again is even worth the side effects if the weight loss has stalled anyway. She also mentions changing injection sites, which is a real thing people try when they think absorption might be the issue.

This is an honest, unsponsored account of something a lot of GLP-1 users actually experience. She's not making wild claims. She's asking a genuine question: is this plateau normal, and what do you do about it? That question deserves a real answer, not a shrug.

Does the science back this up?

Yes, weight loss plateaus on GLP-1 medications are real and well-documented. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) showed that tirzepatide produced significant weight loss over 72 weeks, but the loss rate is not linear. Most of the dramatic early loss happens in the first few months. After that, the body adapts.

The nausea piece is also legitimate. Gastrointestinal side effects, including nausea and dizziness, are among the most commonly reported adverse events in tirzepatide trials. The SURPASS program trials consistently showed nausea rates between 17 and 33 percent depending on dose. Taking breaks, however, is a different story. Stopping and restarting a GLP-1 without medical guidance can affect how the drug titrates in your system, and there's no strong clinical evidence that unstructured "breaks" improve tolerability long-term compared to dose adjustments or slower titration under supervision.

What did they get wrong (or right)?

She gets the plateau experience right. This is not a personal failure or a sign the drug stopped working. Research supports that weight loss slows and stabilizes over time on these medications, and that's actually expected physiology, not a malfunction.

Where things get murkier is the self-managed break strategy. "I take breaks here and then because my nausea is really bad" sounds reasonable, but stopping tirzepatide abruptly and restarting it doesn't follow how the drug is designed to be used. GLP-1 medications are meant to be titrated slowly upward under clinical supervision specifically to reduce nausea. Unplanned stops and restarts can reset that process in unpredictable ways and may not actually help long-term tolerability the way a supervised dose reduction would.

She also mentions changing injection sites, which is fine practice for skin health but is unlikely to be the driver of a multi-month plateau. That's probably not the variable that matters most here.

What should you actually know?

Weight loss plateaus on tirzepatide are not a sign the medication has failed. Research from the SURMOUNT-1 trial shows that meaningful weight loss continues through 72 weeks, but the rate slows considerably after initial losses. A plateau after months of use is consistent with how the drug actually works.

If nausea is severe enough to prompt self-managed breaks, that's a signal to talk to a prescriber about dose adjustment, not to stop and restart without guidance. There are anti-nausea strategies, timing adjustments, and dosing protocols that can help. Going rogue with your injection schedule is not the evidence-based move here.

Dizziness alongside nausea also warrants a clinical conversation. It can be benign, related to the GI effects, or it can signal something that needs evaluation. Mentioning it to a provider matters.

• Plateaus are expected and documented, not a sign of drug failure.
• Nausea management should involve your prescriber, not unstructured breaks.
• Dizziness combined with nausea should be flagged to a clinician.
• Injection site rotation is good practice but unlikely to break a weight loss plateau.

The bottom line

@notdaniflores_ is sharing a real and relatable experience, and she's not spreading misinformation. The plateau is real. The nausea is real. Her frustration is completely understandable. But the self-managed break strategy she's using instead of working with a provider to adjust her dose is the part that could actually make her experience worse over time, not better. The answer to "should I keep taking it" is one that belongs in a clinical conversation, not a comment section.